Amgen (AMGN) Short-Term Debt issuances (2011 - 2017)
Amgen (AMGN) posted Short-Term Debt issuances of $540.0 million for Q3 2017, up 16.88% on a QoQ basis from $462.0 million in Q4 2011.
Powered by 
Analysis
Amgen (AMGN) Short-Term Debt issuances (2011 - 2017) Analysis & Trends
Amgen has reported Short-Term Debt issuances for 2 years, with the latest figure at $540.0 million in Q3 2017.
- On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $540.0 million in Q3 2017; TTM through Sep 2018 was $540.0 million, a 46.11% decrease from a year earlier, with the FY2011 full-year figure at $762.0 million, changed N/A from the prior year.
- Short-Term Debt issuances was $540.0 million for Q3 2017 at Amgen, up from $462.0 million in the prior quarter.
- The five-year high for Short-Term Debt issuances was $540.0 million in Q3 2017, with the low at $540.0 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | - |